C5 and meningococcal infection: For example, C5-inhibitor ECU, which has clinical efficacy in diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder (17), is also increasing the risk for meningococcal infections (43).